Mariantonia Ferrara

Dr. Mariantonia Ferrara

Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Eye
Verified
Journal Article
Closed access
PDF file
MFMariantonia Ferrara
Mariantonia Ferrara
Vito RomanoVito Romano
Vito Romano
DSDavid H Steel
David H Steel
RGRajen Gupta
Rajen Gupta
Claudio IovinoClaudio Iovino
Claudio Iovino
MRMario R. Romano
Mario R. Romano

1 March 2021 in Eye
Verified
Journal Article
Open access
PDF file
MFMariantonia Ferrara
Mariantonia Ferrara
GLGaia Lugano
Gaia Lugano
MSMaria Teresa Sandinha
Maria Teresa Sandinha
VKVictoria R. Kearns
Victoria R. Kearns
BGBrendan Geraghty
Brendan Geraghty
DSDavid H Steel
David H Steel
Studying the biomechanical properties of biological tissue is crucial to improve our understanding of disease pathogenesis. The biomechanical characteristics of the cornea, sclera and the optic nerve head have been well addressed with an extensive literature and an in-depth understanding of their significance whilst, in comparison, knowledge of the retina and choroid is relatively limited. Knowledge of these tissues is important not only to clarify the underlying pathogenesis of a wide variety of retinal and vitreoretinal diseases, including age-related macular degeneration, hereditary retinal dystrophies and vitreoretinal interface diseases but also to optimise the surgical handling of retinal tissues and, potentially, the design and properties of implantable retinal prostheses and subretinal therapies. Our aim with this article is to comprehensively review existing knowledge of the biomechanical properties of retina, internal limiting membrane (ILM) and the Bruch’s membrane–choroidal complex (BMCC), highlighting the potential implications for clinical and surgical practice. Prior to this we review the testing methodologies that have been used both in vitro, and those starting to be used in vivo to aid understanding of their results and significance.

31 January 2022 in Survey of Ophthalmology
Verified
Journal Article
Closed access
MRMario R Romano
Mario R Romano
TRTommaso Rossi
Tommaso Rossi
ABAlfredo Borgia
Alfredo Borgia
FCFiammetta Catania
Fiammetta Catania
TSTania Sorrentino
Tania Sorrentino
MFMariantonia Ferrara
Mariantonia Ferrara

14 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SHSarah Hammadi
Sarah Hammadi
NTNikolaos Tzoumas
Nikolaos Tzoumas
MFMariantonia Ferrara
Mariantonia Ferrara
IMIngrid Porpino Meschede
Ingrid Porpino Meschede
KLKatharina Lo
Katharina Lo
DSDavid H Steel
David H Steel
The complement system is crucial for immune surveillance, providing the body’s first line of defence against pathogens. However, an imbalance in its regulators can lead to inappropriate overactivation, resulting in diseases such as age-related macular degeneration (AMD), a leading cause of irreversible blindness globally affecting around 200 million people. Complement activation in AMD is believed to begin in the choriocapillaris, but it also plays a critical role in the subretinal and retinal pigment epithelium (RPE) spaces. Bruch’s membrane (BrM) acts as a barrier between the retina/RPE and choroid, hindering complement protein diffusion. This impediment increases with age and AMD, leading to compartmentalisation of complement activation. In this review, we comprehensively examine the structure and function of BrM, including its age-related changes visible through in vivo imaging, and the consequences of complement dysfunction on AMD pathogenesis. We also explore the potential and limitations of various delivery routes (systemic, intravitreal, subretinal, and suprachoroidal) for safe and effective delivery of conventional and gene therapy-based complement inhibitors to treat AMD. Further research is needed to understand the diffusion of complement proteins across BrM and optimise therapeutic delivery to the retina.

30 May 2013 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
DSDiego Strianese
Diego Strianese
RPRaffaele Piscopo
Raffaele Piscopo
AEAndrea Elefante
Andrea Elefante
MNManuela Napoli
Manuela Napoli
CCChiara Comune
Chiara Comune
GBGiulio Bonavolontà
Giulio Bonavolontà
Background The purpose of this retrospective follow-up study is to evaluate the prevalence of patients with thyroid eye disease presenting with apparent unilateral proptosis and determine the occurrence of exophthalmos in contralateral non-proptotic eye over the time. Associated features with this event were evaluated. Methods A cohort of 655 consecutive patients affected by thyroid eye disease with a minimum follow-up of 10 years was reviewed. Exophthalmos was assessed by using both Hertel exophthalmometer and computed tomography (CT). The influence of age, gender, hormonal status and of different therapies such as corticosteroids, radiotherapy and surgical decompression on this disease progression was evaluated. Results A total of 89 patients (13.5%) (95% confidence interval [CI] 15%-10%) had clinical evidence of unilateral exophthalmos at the first visit. Among these, 13 patients (14%) (95% CI 22%-7%) developed subsequent contralateral exophthalmos. The increase of protrusion ranged from 2 to 7 mm (mean of 4.2). The time of onset varied from 6 months to 7 years (mean time: 29 months). Smoking status, young age and surgical decompression are significantly associated with development of contralateral proptosis (p< .05). Conclusions Asymmetric thyroid eye disease with the appearance of unilateral exophthalmos at the initial examination is a fairly frequent event, while subsequent contralateral proptosis occurs less commonly. However, physicians should be aware that young patients, particularly if smokers, undergoing orbital decompression in one eye may need further surgery on contralateral side over time.

5 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MFMariantonia Ferrara
Mariantonia Ferrara
Giulia CocoGiulia Coco
Giulia Coco
TSTania Sorrentino
Tania Sorrentino
KJKirti Jasani
Kirti Jasani
GMGeorge Moussa
George Moussa
Mario R. RomanoMario R. Romano
Mario R. Romano
Silicone oils (SO) are used as long-term intraocular tamponades and have an irreplaceable role in vitreoretinal surgery. They can, however, be associated with multiple and potentially severe complications, involving different ocular tissues, in particular retina and cornea. Recent advances in ophthalmic imaging have allowed the precise characterization of retinal and corneal microstructural changes, at a subclinical level. This detailed analysis of SO-related retinal and corneal changes has improved our understanding of their pathogenesis and offer the potential for optimized monitoring and management of patients with SO-filled eyes. This review aims to provide clinicians and ophthalmic scientists with an updated and comprehensive overview of the corneal and retinal changes associated with SO tamponade.